These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9286632)

  • 21. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.
    Planté-Bordeneuve V; Davis MB; Maraganore DM; Marsden CD; Harding AE
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):911-3. PubMed ID: 8057112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
    Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease.
    Joost O; Taylor CA; Thomas CA; Cupples LA; Saint-Hilaire MH; Feldman RG; Baldwin CT; Myers RH
    Mov Disord; 1999 Jul; 14(4):590-5. PubMed ID: 10435495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.
    Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
    Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochrome P450 CYP2D6.
    Wolf CR; Smith G
    IARC Sci Publ; 1999; (148):209-29. PubMed ID: 10493260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
    Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
    Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
    Singh M; Khanna VK; Shukla R; Parmar D
    Dis Markers; 2010; 28(2):87-93. PubMed ID: 20364044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
    Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
    Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of CYP2D6*41 (G2988A) allele in Saudi Arabians.
    Al-Dosari MS; Al-Jenoobi FI; Alkharfy KM; Alghamdi AM; Bagulb KM; Parvez MK; Al-Mohizea AM; Al-Muhsen S; Halwani R
    Environ Toxicol Pharmacol; 2013 Nov; 36(3):1063-7. PubMed ID: 24121619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population.
    Woo SI; Kim JW; Seo HG; Park CH; Han SH; Kim SH; Kim KW; Jhoo JH; Woo JI
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):373-7. PubMed ID: 11442888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands.
    Halling J; Petersen MS; Grandjean P; Weihe P; Brosen K
    Pharmacogenet Genomics; 2008 Mar; 18(3):209-12. PubMed ID: 18300942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease and CYP2D6 polymorphism in Asian populations: A meta-analysis.
    Persad AS; Stedeford T; Tanaka S; Chen L; Banasik M
    Neuroepidemiology; 2003; 22(6):357-61. PubMed ID: 14557687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C; Lafitte JJ
    Clin Neuropharmacol; 1996 Jun; 19(3):213-21. PubMed ID: 8726540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of the CYP2D6 gene polymorphism on the risk of pemphigoid.
    Rychlik-Sych M; Barańska M; Wojtczak A; Skrętkowicz J; Żebrowska A; Waszczykowska E
    Int J Dermatol; 2015 Dec; 54(12):1396-401. PubMed ID: 26235034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.
    Chen S; Chou WH; Blouin RA; Mao Z; Humphries LL; Meek QC; Neill JR; Martin WL; Hays LR; Wedlund PJ
    Clin Pharmacol Ther; 1996 Nov; 60(5):522-34. PubMed ID: 8941025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease].
    Tao E; Liu Z; Chen B; Pan X; Shao M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-gene and gene-environment interaction on the risk of Parkinson's disease.
    Singh NK; Banerjee BD; Bala K; Chhillar M; Chhillar N
    Curr Aging Sci; 2014; 7(2):101-9. PubMed ID: 25101650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
    Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
    Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism of CYP2D6 in patients with cardiovascular disease -- a cohort study.
    Teh LK; Zilfalil BA; Marina I; Rosemi BS; Ismail R
    J Clin Pharm Ther; 2004 Dec; 29(6):559-64. PubMed ID: 15584944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P450 enzymes and Parkinson's disease: the story so far.
    Riedl AG; Watts PM; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):212-20. PubMed ID: 9539332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.